Sermorelin can prompt the body to release growth hormone. That does not establish that it turns back aging, builds muscle like a steroid or fixes sleep. The most common sermorelin myths take a real hormone response and turn it into a result the study never showed.
Sermorelin is a synthetic peptide, a manufactured short chain of protein building blocks. It copies part of growth hormone-releasing hormone (GHRH), the body's signal to release growth hormone. The signal and the result are different things. These ten claims show where the evidence stops.
Sermorelin myths: what the grades mean
Supported means the evidence backs the claim as written. Partly means one part holds up. Not supported means the claim goes beyond the findings. Unknown means the comparison remains unsettled. An unsupported promise is not proof that a treatment cannot help anyone.
1. “It's the same thing as HGH.”
Not supported: human growth hormone (HGH) treatment supplies the hormone itself. Sermorelin prompts the pituitary, a small gland beneath the brain, to release it. Vitiello and colleagues' 2006 study in Neurobiology of Aging describes this difference between supplying a hormone and stimulating its release. The sermorelin versus HGH comparison covers the practical details.
Sharing a hormone pathway doesn't make two medicines interchangeable or establish the same benefits and risks.
2. “Geref disappeared because it was unsafe.”
Not supported: the Food and Drug Administration (FDA) reached a different conclusion. Its Federal Register determination, published March 4, 2013, found that both Geref products were not withdrawn for reasons of safety or effectiveness. The manufacturer discontinued them in 2008; withdrawal of their approvals took effect June 18, 2009.
That finding answers why the products left. It does not prove that every later preparation is safe, or that adult wellness claims were established.
3. “It turns back aging.”
Not supported: selected test improvements are narrower than younger health or longer life. In Vitiello's study, 100 healthy older adults entered and 89 completed six months. Some thinking-test scores improved compared with placebo, an inactive treatment used for comparison.
The paper did not establish longer life or prevention of age-related illness. The sermorelin clinical-trials guide separates those outcomes. A finding on a thinking test deserves attention without being stretched into an anti-aging promise.
4. “It builds muscle like a steroid.”
Not supported: a growth-hormone signal is not evidence of steroid-like muscle gains. Vittone and colleagues, Metabolism, 1997, found no change in scanned muscle measurements after six weeks in 11 older men, although two of six strength measures improved. Sermorelin also differs from anabolic steroids, testosterone-like drugs, as the steroid comparison explains.
As of October 1, 2026, the day this article was written, the World Anti-Doping Agency's September 21 announcement introduces its 2027 list, effective January 1, 2027. The list names sermorelin under S2.2.4, among growth-hormone-releasing factors prohibited in and out of competition. A sports prohibition does not establish a muscle benefit or make the molecule a steroid.
5. “Everyone's IGF-1 goes up.”
Not supported: IGF-1 is a growth factor made largely by the liver in response to growth hormone. The small studies did not all find the same change. Corpas and colleagues, The Journal of Clinical Endocrinology & Metabolism, 1992, found an increase after 14 days only with the higher tested regimen in 10 older men. Vittone found none despite higher overnight growth-hormone release.
How sermorelin responses are measured explains why a hormone response cannot guarantee a particular lab result.
6. “Results show up in days.”
Partly: a hormone response can happen quickly, but that is not the same as feeling or looking different. Losa and colleagues, Klinische Wochenschrift, 1984, tested five volunteers and found peak growth-hormone levels 15–30 minutes after an injection into a vein. The experiment did not measure sleep, muscle growth or daily energy.
A fast signal cannot supply a first-week results calendar. The prescriber defines which outcome matters and how it will be assessed.
7. “It's natural, so there are no side effects.”
Not supported: copying a natural signal does not make a manufactured medicine free of side effects. Vitiello's trial reported two departures considered likely related to treatment: injection-site hives and feeling generally unwell. Months of observation also cannot settle years of use.
As of October 1, 2026, the day this article was written, a July 3 case report in Frontiers in Surgery adds a question about long-term exposure. It describes swallowing trouble from a neck bone spur in someone reporting years of several growth-hormone drugs, including sermorelin. The drug history was unverified, and age-related changes and previous injury could explain the finding. It cannot establish that sermorelin caused it or estimate anyone's risk.
8. “It fixes sleep.”
Not supported: sleep and growth hormone are connected, but changing one does not reliably improve the other. Vitiello and colleagues' 2001 preliminary report in Dialogues in Clinical Neuroscience found slightly worse reported sleep quality with nightly sermorelin rather than improvement. In Khorram and colleagues' 1997 JCEM study, sleep quality was unchanged in 19 adults.
That study used a modified GHRH molecule, not ordinary sermorelin. The sermorelin sleep-evidence guide explains why sleep-lab findings and treatment results differ.
9. “Geref's old approval covers today's prescription.”
Not supported: historical approval belongs to the historical product. As of October 1, 2026, the day this article was written, FDA's Orange Book data lists the Geref products as discontinued. No FDA-approved sermorelin product is currently marketed.
It is compounded, meaning a pharmacy prepares it for a prescription. That is different from an FDA-approved product: the formulation offered here is not FDA-approved. Promise offers sermorelin by prescription, after a licensed provider reviews your request. FDA's compounding explanation distinguishes that preparation from premarket review of safety, effectiveness and quality.
10. “A longer-acting alternative must work better.”
Unknown: lasting longer and producing a better outcome are separate questions. Teichman and colleagues' 2006 JCEM trials tested CJC-1295 with DAC, a chemical attachment that lets it bind a blood protein and last longer. They measured sustained hormone changes, not superiority over sermorelin. They also did not test the CJC-1295/ipamorelin combination.
The days-long findings belong to that specific DAC form. They cannot establish the duration or benefits of another formulation, including a compounded blend.
What a prescription conversation can settle
The useful starting point is the goal, the exact preparation and the evidence for that goal. A clinician can distinguish a lab change from a change that matters in daily life. The studies above cannot establish the results of a compounded product they did not test.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. The prescriber sets the dose and follow-up plan, including how response and side effects will be judged.
